NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY;CHUGAI SEIYAKU KABUSHIKI KAISHA
发明人:
Takako MATSUOKA,Manabu ARAKI,Takashi YAMAMURA
申请号：
US16609053
公开号：
US20200148760A1
申请日:
2018.05.01
申请国别(地区):
US
年份:
2020
代理人:
摘要：
It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.
